A new drug, combined with chemotherapy, halted the progression of metastatic pancreatic cancer in 90% of patients

Share

Early clinical trial results show that a daily pill, daraxonrasib, combined with chemotherapy halted tumour growth in almost all patients with advanced pancreatic cancer. In one in every 12 patients, scans showed no remaining signs of the disease.

The study involved 61 patients newly diagnosed with metastatic pancreatic cancer, who were followed by medical professionals for an average of a year and a half. According to data presented at the European Organisation for Research and Treatment of Cancer (EORTC) conference:

  • Tumour growth was halted in 90% of patients;

  • Tumours shrank or disappeared in more than 60% of patients;

  • In approximately 8% of patients (one in every 12), computed tomography (CT) scans showed no remaining evidence of the tumour.

Daraxonrasib is a KRAS inhibitor that has already been approved in the United States. The drug targets RAS mutations found in most pancreatic tumours and blocks their activity, thereby preventing cancer cells from multiplying. Since similar mutations are also found in dozens of other types of cancer, including lung and ovarian cancer, scientists believe the medication could potentially be used to treat other types of tumours in the future.

Cancer Research UK described the results as the “biggest leap forward in pancreatic cancer treatment in decades”. According to Dr Sam Godfrey, a representative of the organisation, the new drug has successfully targeted a mechanism that was previously considered inaccessible to medicines.

Dr Wungki Park, a specialist at Memorial Sloan Kettering Cancer Center (USA) involved in the study, explained that the combination therapy not only demonstrates a high response rate but also nearly doubles the duration of disease control, potentially translating into longer patient survival. Professor Elena Garralda, chair of the EORTC conference, also noted that this approach has the potential to significantly improve both overall survival and the time before the tumour starts growing again.

Nevertheless, doctors urge caution, emphasising that the drug does not completely cure the disease. It is not yet known how long it can keep the tumour under control. Although some patients remained free of disease recurrence during the 18-month follow-up period, the absence of visible tumours on scans does not automatically mean a complete recovery. Longer-term studies are needed to determine how durable and lasting the remission is.

Pancreatic cancer has one of the lowest survival rates among common cancers. Despite standard chemotherapy, tumours often begin growing again, and in advanced stages, most patients survive for only a few months after diagnosis. In the United Kingdom alone, approximately 11,500 new cases of pancreatic cancer and around 10,200 deaths are recorded each year.

BBC

Share

spot_img

Other news